Kisplyx

Lenvatinib, the active ingredient in Kisplyx, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats advanced differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma in adult patients. GNH USA supplies Kisplyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenvatinib is indicated for malignancies driven by angiogenesis and growth‑factor signaling.

- Differentiated thyroid cancer: Improves progression‑free survival in patients with radioactive‑iodine refractory disease. - Renal cell carcinoma: Reduces tumor growth in advanced clear‑cell RCC. - Hepatocellular carcinoma: Extends overall survival in patients with unresectable HCC.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Diarrhea: may be mild to moderate. - Fatigue: persistent tiredness. - Decreased appetite: reduced food intake. - Nausea: occasional upset stomach. - Weight loss: unintended loss of body mass.

Serious or Rare Side Effects: - Hepatic failure: signs of liver dysfunction. - Arterial thromboembolism: risk of clot formation. - Severe hemorrhage: significant bleeding events. - Gastrointestinal perforation or fistula: serious GI complications. - Severe infection: opportunistic infections. - Cardiac dysfunction: reduced heart function.

Patients should be monitored for specific safety concerns before and during therapy.

- Blood pressure monitoring: check regularly and manage hypertension promptly. - Liver function assessment: evaluate enzymes and bilirubin before initiation and periodically. - Proteinuria screening: test urine for abnormal protein levels. - Drug interaction review: assess concomitant medications that affect CYP3A4. - Pregnancy avoidance: drug is contraindicated in pregnancy due to unknown fetal risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lenvatinib may interact with several drug classes, requiring caution.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenvatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Digoxin: potential increase in serum levels. - Statins metabolised by CYP3A4 (e.g., simvastatin): monitor for myopathy. - Proton‑pump inhibitors: may alter absorption. - Antihypertensives: adjust dose as blood pressure may change.